| Field | Specification |
|---|---|
| Target | |
| Alternative names | Cyclic AMP-dependent transcription factor ATF-6 alpha;cAMP-dependent transcription factor ATF-6 alpha;Activating transcription factor 6 alpha;ATF6-alpha;Processed cyclic AMP-dependent transcription factor ATF-6 alpha;ATF6; |
| UniProt # | |
| Host | |
| Clonality | |
| Isotype | |
| Reactivity | |
| Applications | |
| Immunogen | E.coli-derived human ATF6 recombinant protein (Position: Q79-Q670). |
| Molecular weight | |
| Purification | |
| Reconstitution | |
| Cellular localization | |
| Concentration | |
| Form | Lyophilized |
| Storage | |
| Catalog no. (Mfr.) | |
| Main SKU |
Product Overview
This rabbit polyclonal antibody recognizes cyclic AMP-dependent transcription factor ATF-6 alpha (gene ATF6) in human samples and is validated for Western blot, IHC, ICC/IF, flow cytometry and ELISA. The predicted molecular weight is 74.6 kDa, and the supplier reports an observed band at about 90–100 kDa.
Cyclic AMP-dependent transcription factor ATF-6 alpha (ATF6) is an ER membrane protein that senses the buildup of misfolded proteins. Under ER stress it moves to the Golgi, where proteases release its cytosolic bZIP domain, which enters the nucleus to activate chaperones and other unfolded protein response genes.
| Target | Cyclic AMP-dependent transcription factor ATF-6 alpha (gene ATF6; UniProt P18850, human) |
|---|---|
| Host / Clonality / Isotype | Rabbit / Polyclonal / Rabbit IgG |
| Reactivity | Human |
| Form | Lyophilized |
| Formulation | Per vial: 4 mg trehalose; 0.9 mg NaCl; 0.2 mg Na2HPO4 |
| Calculated MW | 74.6 kDa |
| Observed MW | 90–100 kDa |
| Storage | As supplied: −20 °C for up to 12 months from receipt. After reconstitution: 4 °C for up to 1 month, or aliquot and keep at −20 °C for up to 6 months. Avoid repeated freeze–thaw cycles. |
Validated Applications
| Western blot | 0.25–0.5 µg/mL (Human) |
|---|---|
| IHC (paraffin sections) | 2–5 µg/mL (Human) |
| Immunocytochemistry / Immunofluorescence | 5 µg/mL (Human) |
| Flow cytometry (fixed cells) | 1–3 µg/1×106 cells (Human) |
| ELISA | 0.1–0.5 µg/mL |
Samples with a confirmed band (WB): human HeLa cells, human 293T whole cellhuman K562 whole cellhuman MCF-7 cells.
Recommended loading (WB): 20–40 µg of total protein per lane.
Conditions in the example images (WB): 5–20% gradient SDS-PAGE under reducing conditions, 30 µg lysate per lane, transfer to nitrocellulose membrane, blocking in 5% non-fat milk, primary antibody at 0.5 µg/mL overnight at 4 °C, HRP-conjugated secondary antibody at 1:5000, ECL detection.
Samples with confirmed staining (IHC): human kidney tissue.
Recommended antigen retrieval: heat-mediated, in TE buffer (pH 9.0); citrate buffer (pH 6.0) can be used instead.
Conditions in the example images (IHC): heat-mediated antigen retrieval in EDTA buffer (pH 8.0).
Samples with confirmed staining (ICC/IF): SiHa cells.
Samples with a confirmed signal (flow cytometry): SiHa cells.
Immunogen
Recombinant human ATF6 fragment (Gln79–Gln670), expressed in E. coli.
Reactivity Notes
The supplier lists reactivity with human. UniProt places cyclic AMP-dependent transcription factor ATF-6 alpha in the endoplasmic reticulum membrane and Golgi apparatus membrane. Tissue expression noted by UniProt (human): Ubiquitous. The samples tested by the supplier (listed above) are a practical starting point for positive controls.
Safety
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
